Surface Ophthalmics

Founded in 2018, Surface Ophthalmics (Surface) stands as a pioneering biopharmaceutical firm devoted to the discovery and market introduction of advanced treatments for diseases affecting the ocular surface. Our mission is to address critical care needs within eye care by harnessing in-depth knowledge, a dynamic strategy, a focus on efficiency, and distinctive clinical benefits. Surface boasts a remarkable team of leaders and advisors, each distinguished by their outstanding leadership qualities, exceptional skills, and comprehensive industry knowledge—factors that are vital to the company’s achievements.